CL2024002455A1 - Inhibidores de nlrp3 - Google Patents

Inhibidores de nlrp3

Info

Publication number
CL2024002455A1
CL2024002455A1 CL2024002455A CL2024002455A CL2024002455A1 CL 2024002455 A1 CL2024002455 A1 CL 2024002455A1 CL 2024002455 A CL2024002455 A CL 2024002455A CL 2024002455 A CL2024002455 A CL 2024002455A CL 2024002455 A1 CL2024002455 A1 CL 2024002455A1
Authority
CL
Chile
Prior art keywords
compounds
nlrp3
inhibitors
disorders
nlrp3 inhibitors
Prior art date
Application number
CL2024002455A
Other languages
English (en)
Spanish (es)
Inventor
Zhang Xiaoyan
ALAM Rauful
BEJCEK Lauren
HOSSEYNI Seyedmorteza
HUARTE Eduardo
Li Jing
Liu Yao
NIEDERER Kyle
PILLAI Meenu
RASTELLI Ettore
Sydorenko Nadiya
Zhang Nanjing
Zheng Tianyi
B Gilbert Bradley
N Parker Erica
G Woll Matthew
- Handoko
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/075421 external-priority patent/WO2023028534A1/en
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of CL2024002455A1 publication Critical patent/CL2024002455A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2024002455A 2022-02-18 2024-08-15 Inhibidores de nlrp3 CL2024002455A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263311463P 2022-02-18 2022-02-18
PCT/US2022/075421 WO2023028534A1 (en) 2021-08-25 2022-08-24 Inhibitors of nlrp3

Publications (1)

Publication Number Publication Date
CL2024002455A1 true CL2024002455A1 (es) 2025-01-17

Family

ID=87579158

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002455A CL2024002455A1 (es) 2022-02-18 2024-08-15 Inhibidores de nlrp3

Country Status (14)

Country Link
US (1) US20250179078A1 (https=)
EP (1) EP4479045A4 (https=)
JP (1) JP2025509088A (https=)
KR (1) KR20240164495A (https=)
CN (2) CN118302417A (https=)
AU (1) AU2023221847A1 (https=)
CA (1) CA3243870A1 (https=)
CL (1) CL2024002455A1 (https=)
CO (1) CO2024011162A2 (https=)
CR (1) CR20240345A (https=)
IL (1) IL315027A (https=)
MX (1) MX2024010092A (https=)
PE (1) PE20250604A1 (https=)
WO (1) WO2023159148A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4362946A4 (en) * 2021-06-29 2025-05-21 Zomagen Biosciences Ltd Nlrp3 modulators
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
JP2025524640A (ja) * 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
EP4667468A1 (en) 2023-02-14 2025-12-24 Shenzhen Zhongge Biological Technology Co., Ltd. Compound for inhibiting nlrp3, preparation method, and use
US20250195511A1 (en) * 2023-12-14 2025-06-19 Merck Sharp & Dohme Llc Indazole derivatives useful as inhibitors of nod-like receptor protein 3
WO2025133307A1 (en) * 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2026057747A1 (en) 2024-09-11 2026-03-19 Ac Immune Sa Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
WO2026067767A1 (zh) * 2024-09-30 2026-04-02 普罗思特(南京)生物科技有限公司 取代的哒嗪衍生物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702611A (en) * 2012-05-16 2016-10-28 Cellzome Ltd Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
WO2014007217A1 (ja) * 2012-07-02 2014-01-09 大鵬薬品工業株式会社 イミダゾオキサジン化合物による抗腫瘍効果増強剤
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
AU2021257619A1 (en) * 2020-04-15 2022-12-15 Janssen Pharmaceutica Nv Pyrazolo[1,5-d][1,2,4]triazine-5(4H)-acetamides as inhibitors of the NLRP3 inflammasome pathway
EP4362946A4 (en) * 2021-06-29 2025-05-21 Zomagen Biosciences Ltd Nlrp3 modulators
CR20240093A (es) * 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法

Also Published As

Publication number Publication date
CO2024011162A2 (es) 2024-12-09
EP4479045A4 (en) 2026-03-04
EP4479045A2 (en) 2024-12-25
CR20240345A (es) 2024-09-16
AU2023221847A1 (en) 2024-09-05
CA3243870A1 (en) 2023-08-24
WO2023159148A3 (en) 2023-10-05
IL315027A (en) 2024-10-01
KR20240164495A (ko) 2024-11-19
WO2023159148A2 (en) 2023-08-24
MX2024010092A (es) 2024-12-06
JP2025509088A (ja) 2025-04-11
US20250179078A1 (en) 2025-06-05
PE20250604A1 (es) 2025-02-26
CN118302417A (zh) 2024-07-05
CN119212699A (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
CO2024011162A2 (es) Inhibidores de nlrp3
ECSP24014832A (es) Inhibidores de nlrp3
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
CR20210552A (es) Inhibidores del inflamasoma nlrp3
CL2020000747A1 (es) Formulaciones de niraparib.
CR20220031A (es) Inhibidores tricíclicos de kars dependientes de akr1c3
MX2025002086A (es) Inhibidores novedosos de inflamasoma nlrp3
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2017014621A (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma.
DOP2025000013A (es) Inhibidores de inflamasoma nlrp3
AR123685A1 (es) Antagonistas del mrgx2
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
UY39484A (es) Inhibidores de interleucina-17
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
CL2023002632A1 (es) Derivados de 3h,4h-tieno [2,3-d]pirimidin-4-ona como inhibidores de trpa1
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
ECSP21062210A (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
CO2022012880A2 (es) Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen
UY38550A (es) Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados
MX2020009645A (es) Inhibidores de secrecion de proteinas basados en triazaciclododecansulfonamida ("tcd").
AR134411A1 (es) Compuestos de uracilo
CO2023014012A2 (es) Derivados de tetrahidrotieno piridina como inhibidores de ddr